CYM-5520|cas:1449747-00-5|西域试剂

CYM-5520,99.79%

产品编号：Bellancom-100953| CAS NO：1449747-00-5| 分子式：C₂₁H₁₉N₃O₂| 分子量：345.39

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100953	￥1180.00	杭州北京（现货）
Bellancom-100953	￥1780.00	杭州北京（现货）
Bellancom-100953	￥3200.00	杭州北京（现货）
Bellancom-100953	￥4800.00	杭州北京（现货）
Bellancom-100953	￥7200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CYM-5520

产品介绍

CYM-5520 是一种选择性的变构鞘氨醇 1-磷酸受体 2 (S1PR2) 激动剂，EC₅₀ 为 480 nM。CYM-5520 不激活 S1PR1、S1PR3、S1PR4 和 S1PR5 受体。CYM-5520 可以在 S1PR2 受体中与 S1P 结合。CYM-5520 可用于骨质疏松症研究。

生物活性

CYM-5520 is a selective and allosteric sphingosine 1-phosphate receptor 2 (S1PR2) agonist with an EC₅₀ of 480 nM. CYM-5520 does not activate S1PR1, S1PR3, S1PR4 and S1PR5 receptors. CYM-5520 can co-bind in the S1PR2 receptor with S1P. CYM-5520 can be used for osteoporosis research.

体外研究

CYM-5520 (EC₅₀ of 1.6 μM) is a full agonist for wild type S1PR2. Stimulation of cells expressing the triple mutant S1PR2 with S1P does not elicit a rise in luciferase activity, whereas the CYM-5520 is an agonist with an EC₅₀ of 1.5 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

CYM-5520 (10 mg/kg; i.p.; 5 consecutive days per week; for 6 weeks) treatment clearly increases long bone and vertebral bone mass in osteopenic ovariectomized mice. CYM-5520 also increases osteoblast number, osteoid surface and alkaline phosphatase, and plasma concentrations of the osteoanabolic marker procollagen I C-terminal propeptide are also elevated.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ovariectomized 12 weeks old C57Bl6J mice
Dosage:	10 mg/kg
Administration:	i.p.; 5 consecutive days per week; for 6 weeks
Result:	Corrected ovariectomy-induced osteopenia in mice by inducing new bone formation.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ovariectomized 12 weeks old C57Bl6J mice
Dosage:	10 mg/kg
Administration:	i.p.; 5 consecutive days per week; for 6 weeks
Result:	Corrected ovariectomy-induced osteopenia in mice by inducing new bone formation.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (144.76 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8953 mL	14.4764 mL	28.9528 mL
5 mM	0.5791 mL	2.8953 mL	5.7906 mL
10 mM	0.2895 mL	1.4476 mL	2.8953 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。